This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The trial was terminated early because of highly significant reduction in mortality in the poractant alfa group.

Mortality data was analysed for 199 neonates:

  • in the Porcactant alpha group mortality was 14.1%
  • in the Pumactant group mortality was 31%
  • p=0.006

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.